Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.52 |
| ▸ | STK4 | Q13043 | 10/20 | 0.51 |
| ▸ | JAK1 | P23458 | 3/20 | 0.51 |
| ▸ | JAK3 | P52333 | 3/20 | 0.51 |
| ▸ | SYK | P43405 | 2/20 | 0.51 |
| ▸ | CDK2 | P24941 | 4/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.49 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.49 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17669875 | 0.93 | JAK1 (0.59) | AURKAAURKBJAK1JAK3SYK | |
| SCHEMBL1475290 | 0.90 | JAK3 (0.62) | AURKAAURKBSTK4JAK1JAK3 | |
| SCHEMBL1475146 | 0.84 | BRD4 (0.52) | AURKAAURKBSTK4JAK1JAK3 | |
| SCHEMBL1474404 | 0.84 | JAK3 (0.72) | AURKAAURKBJAK1JAK3SYK | |
| SCHEMBL3997103 | 0.83 | SYK (0.55) | AURKAAURKBSTK4JAK1JAK3 | |
| SCHEMBL1477012 | 0.83 | JAK1 (0.60) | AURKAAURKBSTK4JAK1JAK3 | |
| SCHEMBL4002118 | 0.83 | STK4 (0.49) | AURKAAURKBSTK4JAK1JAK3 | |
| SCHEMBL1474895 | 0.83 | STK4 (0.50) | AURKAAURKBSTK4JAK1JAK3 | |
| SCHEMBL19527798 | 0.82 | SYK (0.50) | AURKAAURKBSTK4JAK1JAK3 | |
| SCHEMBL1475129 | 0.82 | STK4 (0.47) | AURKAAURKBSTK4JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732073-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | claimed |
| US-20160102084-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2016-04-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102084-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | AURKA 1039/4885AURKB 555/4885STK4 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.